Barbulescu (2022)
Rheumatoid Arthritis
Rheumatology • National_Database Data • Sweden
Study Metrics
Quality Indicators
Study Information
| First Author: | Barbulescu |
| Publication Year: | 2022 |
| DOI: | https://doi.org/10.1002/cpt.2673 |
| Preprint: | No preprint |
Institution & Funding
| Institution Type: | Academic |
| Institutions: | Karolinska Institutet, Karolinska University Hospital, University of Iceland, Brigham and Women's Hospital/Harvard Medical School |
| Funding: | Declared: Public |
| Funding Institutions: | This work was supported by the Swedish Research Council (grant 2016-01355). S.C.K. is supported by the National Institutes of Health (NIH; grant K24AR078959) |
Study Context
| Disease: | Rheumatoid Arthritis |
| Disease Category: | Rheumatology |
| Data Type: | national_database |
| Geography: | Sweden |
| Eligible Sample: | 509.0 |
| Number of Treatments: | 2 |
Analytical Methods
| Missing Data Method: | Multiple imputation |
| Matching Method: | IPTW |
| Analysis Method: | logistic regression |
| Estimand: | Not defined |
Quality Methods
Target Trial Information
| Target Trial Name: | SWEFOT |
| Registration Number: | CT20080004 |
| Target Trial DOI: | https://doi.org/10.1016/s0140-6736(09)60944-2 |
TTE vs RCT Comparisons
Detailed comparison between Target Trial Emulation results and corresponding Randomized Controlled Trial outcomes.
European Alliance of Associations for Rheumatology (EULAR) good or moderate responders at 9 months
SWEFOTPopulation
Patients with rheumatoid arthritis (RA)
Intervention
Infliximab added to methotrexate therapy
Comparison
Sulfasalazine (SSZ) + hydroxychloroquine (HCQ) added to methotrexate therapy
Outcome
European Alliance of Associations for Rheumatology (EULAR) good or moderate responders at 9 months
RCT Result
1.22
95% CI: [0.98, 1.53]
vs
TTE Result
1.27
95% CI: [0.99, 1.63]
Concordance Assessment
CIs overlap, suggesting concordance
Both point to similar conclusion
European Alliance of Associations for Rheumatology (EULAR) good responders at 9 months
SWEFOTPopulation
Patients with rheumatoid arthritis (RA)
Intervention
Infliximab added to methotrexate therapy
Comparison
Sulfasalazine (SSZ) + hydroxychloroquine (HCQ) added to methotrexate therapy
Outcome
European Alliance of Associations for Rheumatology (EULAR) good responders at 9 months
RCT Result
1.59
95% CI: [1.10, 2.30]
vs
TTE Result
1.48
95% CI: [0.98, 2.24]
Concordance Assessment
CIs overlap, suggesting concordance
Both point to similar conclusion
Transparency Indicators
Overall Transparency Score:
Conflicts & Funding
| Conflicts of Interest: | Declared: Financial |
| COI Institutions: | AbbVie, Bristol Myers Squibb, MSD, Eli Lilly, Pfizer, Roche, Samsung Bioepis, UCB, Roche/Genentech, deCODE genetics |
| Funding Source: | Declared: Public |
| Funding Institutions: | This work was supported by the Swedish Research Council (grant 2016-01355). S.C.K. is supported by the National Institutes of Health (NIH; grant K24AR078959) |